![Edge Therapeutics, Inc.](/common/images/company/N_EDGE.png)
BERKELEY HEIGHTS, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the full-year ended December 31, 2018. Financial Results...
LONDON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- In late November 2018, NetScientific (AIM: NSCI) announced that its portfolio company PDS Biotechnology and Edge Therapeutics (NASDAQ: EDGE) will...
-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a...
BERKELEY HEIGHTS, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended September 30, 2018. Third Quarter...
BERKELEY HEIGHTS, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended June 30, 2018. Second Quarter...
BERKELEY HEIGHTS, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced updated results from its ongoing analyses of the Phase 3 NEWTON 2 study of...
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Edge Therapeutics, Inc. (“Edge” or ''the Company'') (NASDAQ:...
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Edge Therapeutics, Inc. (“Edge” or ''the Company'') (NASDAQ:...
BERKELEY HEIGHTS, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended March 31, 2018. First Quarter...
BERKELEY HEIGHTS, N.J., April 30, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced that its Board of Directors is conducting a comprehensive review of strategic...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales